Generalized Anxiety Disorder Screener-7 (GAD-7)

Abstract

The Generalized Anxiety Disorder Screener-7 (GAD-7) is a concise, 7-item self-report measure designed for screening and assessing symptoms of Generalized Anxiety Disorder (GAD) in both adult and adolescent populations. Developed as a key module within the Patient Health Questionnaire (PHQ), the GAD-7 quickly moved beyond its initial screening function to serve as a diagnostic aid and a tool for monitoring symptom severity over time. Research also supports its utility in screening for other common anxiety disorders, including panic disorder and social anxiety disorder.

The measure utilizes a Likert-type scale to score symptoms based on frequency over the preceding two weeks, yielding a total score from 0 to 21. It has demonstrated excellent psychometric properties, including high internal consistency and strong convergent validity with other established anxiety instruments.

Keywords

Generalized Anxiety Disorder, GAD-7, Patient Health Questionnaire, Screening tool, Anxiety symptoms, Psychometrics, Primary care, Self-report, Validity, Reliability.

Authors

Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams, Bernd Lowe.

Purpose

The primary purpose of the Generalized Anxiety Disorder Screener-7 (GAD-7) is to provide a rapid, efficient screening instrument for Generalized Anxiety Disorder (GAD) in primary care settings. It was specifically developed to address the time constraints associated with longer diagnostic instruments, such as the original Primary Care Evaluation of Mental Disorders (PRIME-MD), allowing for universal screening in time-sensitive clinical environments.

Beyond its primary screening role, the GAD-7 is validated for multiple clinical applications. These include aiding in formal diagnosis of GAD, tracking the severity of anxiety symptoms over the course of treatment (Kertz, Bigda-Peyton, & Bjorgvinsson, 2013), and functioning as a secondary screener for related conditions like social anxiety disorder, panic disorder, and post-traumatic stress disorder (Kroenke et al., 2007).

Construct

The GAD-7 measures the psychological construct of Generalized Anxiety Disorder, focusing on the core symptoms defined by diagnostic criteria, such as excessive worry and related cognitive and somatic manifestations. The scale assesses how frequently an individual has experienced seven specific anxiety symptoms over the preceding two weeks.

The scale utilizes a 4-point Likert-type scale, ranging from zero (“not at all”) to three (“nearly every day”). The resulting total score, which ranges from 0 to 21, corresponds directly to severity levels: scores less than 5 indicate mild anxiety, 10–15 suggest moderate anxiety, and scores of 15 or greater indicate severe anxiety. A cutoff score of 10 or higher is generally recommended for identifying individuals requiring further clinical assessment (Spitzer et al., 2006).

Validity

The GAD-7 has demonstrated robust convergent validity across various validation studies. Specifically, it shows strong correlations with established measures of anxiety, including the Beck Anxiety Inventory (BAI) (r = 0.72) and the anxiety subscale of the Symptom Checklist-90 (SCL-90) (r = 0.74). This indicates that the GAD-7 measures a construct highly similar to those assessed by longer, gold-standard instruments.

In terms of diagnostic accuracy, a systematic review and meta-analysis confirmed that the GAD-7 possesses acceptable properties for identifying GAD, with optimal performance often observed at a cutoff score of 8. At this threshold, the instrument achieved a sensitivity of 0.83 and a specificity of 0.84 (Plummer et al., 2016). Furthermore, cultural adaptations, such as the Spanish version, exhibited excellent criteria validity using Receiver Operating Characteristic (ROC) curve analysis, yielding positive and negative predictive values exceeding 86% (Mills et al., 2014).

Reliability

The reliability of the GAD-7 is considered excellent across diverse populations and settings. The original validation study reported outstanding internal consistency (Cronbach’s alpha = 0.92), indicating that the seven items measure a unified construct related to anxiety severity. This high correlation among items supports the scale’s use as a brief, singular measure of GAD symptoms.

Furthermore, the scale exhibits strong test-retest reliability (r = 0.83), suggesting stability of measurement when administered multiple times to the same individuals over short intervals (Spitzer et al., 2006). Validation studies of culturally adapted versions, including Portuguese and Spanish, consistently corroborate these findings, reporting internal consistency and reliability coefficients above 0.71.

Factor Analysis

Although the original source material does not detail a formal factor analysis, the exceptionally high coefficient of internal consistency (alpha = 0.92) strongly suggests that the GAD-7 operates as a unidimensional scale. This structure is intended to measure a single underlying construct—the severity of Generalized Anxiety Disorder symptoms—making it highly effective as a brief, focused module within the broader PHQ instrument for rapid clinical assessment.

Instrument

Test Type: Self-report measure, Screening tool, Diagnostic aid.

Format: 7 items rated on a 4-point Likert-type scale (0 = not at all, 3 = nearly every day). Total scores range from 0 to 21.

Language Available: Over 20 languages, including English, Spanish, French, Mandarin, and Portuguese.

Population Group: Clinical populations (especially primary care) and general population samples.

Age Group: Adolescents and Adults.

Population Details: Originally validated in a large sample of 2,740 primary care patients in the United States. Also validated for use in adolescent populations.

Test Methodology: Brief self-administered questionnaire, typically requiring only a few minutes to complete.

Keywords

Screening, Diagnosis, Psychometric properties, Test-retest reliability, Convergent validity, Primary care, PHQ, Pfizer, ROC curve, Unidimensional.

Authors

Author ORCID Identifier: Not provided in source content.

Affiliation Email addresses: Not provided in source content.

Correspondence Address: Not provided in source content.

Permissions & Fee and Test Year

The GAD-7 was developed and published in 2006 (Spitzer et al., 2006). The scale, including the manual, instructions, and all existing translations, is available free of charge online at http://www.phqscreeners.com. Explicitly, no permissions or fees are required to reproduce, translate, display, or distribute the instrument, making it highly accessible for both clinical and research use.

A notable disclosure related to the instrument’s origin is that the Patient Health Questionnaire (PHQ), of which GAD-7 is a component, was developed with support from an educational grant provided by Pfizer Inc. While this financial support is acknowledged, the scale’s validity has been confirmed by independent research teams in numerous peer-reviewed journals.

Reference’s

• Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology, 56(6), 893-897.
• Daig, I., Herschbach, P., Lehmann, A., Knoll, N., & Decker, O. (2009). Gender and age differences in domain-specific life satisfaction and the impact of depressive and anxiety symptoms: a general population survey from Germany. Quality of Life Research, 18(6), 669-678. doi:10.1007/s11136-009-9481-3
• Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974). The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behavioral Science, 19(1), 1-15. doi:10.1002/bs.3830190102
• Farrand, P., & Woodford, J. (2013). Measurement of individualised quality of life amongst young people with indicated personality disorder during emerging adulthood using the SEIQoL-DW. Quality of Life Research, 22(4), 829-838. doi:10.1007/s11136-012-0210-y
• Garcia-Campayo, J., Zamorano, E., Ruiz, M. A., Pardo, A., Perez-Paramo, M., Lopez-Gomez, V., . . . Rejas, J. (2010). Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health and Quality of Life Outcomes, 8, 8. doi:10.1186/1477-7525-8-8
• Johnson, J. G., Harris, E. S., Spitzer, R. L., & Williams, J. B. (2002). The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients. Journal of Adolescent Health, 30(3), 196-204.
• Kertz, S., Bigda-Peyton, J., & Bjorgvinsson, T. (2013). Validity of the Generalized Anxiety Disorder-7 scale in an acute psychiatric sample. Clin Psychol Psychother, 20(5), 456-464. doi:10.1002/cpp.1802
• Kroenke, K., Spitzer, R. L., Williams, J. B., Monahan, P. O., & Lowe, B. (2007). Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine, 146(5), 317-325.
• Mills, S. D., Fox, R. S., Malcarne, V. L., Roesch, S. C., Champagne, B. R., & Sadler, G. R. (2014). The Psychometric Properties of the Generalized Anxiety Disorder-7 scale in Hispanic Americans with English or Spanish Language Preference. Cultural Diversity and Ethnic Minority Psychology, 20(3), 463-468. doi:10.1037/a0036523
• Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. General Hospital Psychiatry, 39, 24-31. doi:10.1016/j.genhosppsych.2015.11.005
• Sousa, T. V., Viveiros, V., Chai, M. V., Vicente, F. L., Jesus, G., Carnot, M. J., . . . Ferreira, P. L. (2015). Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health and Quality of Life Outcomes, 13(1), 50. doi:10.1186/s12955-015-0244-2
• Spitzer, R. L., Kroenke, K., & Williams, J. B. (1999). Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA, 282(18), 1737-1744.
• Spitzer, R. L., Kroenke, K., Williams, J. B., & Lowe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092-1097. doi:10.1001/archinte.166.10.1092
• Spitzer, R. L., Williams, J. B., Kroenke, K., Hornyak, R., & McMurray, J. (2000). Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. American Journal of Obstetrics and Gynecology, 183(3), 759-769.
• Spitzer, R. L., Williams, J. B., Kroenke, K., Linzer, M., deGruy, F. V., 3rd, Hahn, S. R., . . .Johnson, J. G. (1994). Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA, 272(22), 1749-1756.

Items of the Generalized Anxiety Disorder Screener-7 (GAD-7)

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

• Feeling nervous, anxious or on edge
• Not being able to stop or control worrying
• Worrying too much about different things